Anadys Pharmaceuticals, Inc. (ANDS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Anadys Pharmaceuticals, Inc. (ANDS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (27)	11/5/2006 3:38:00 PM
From: DewDiligence_on_SI	Read Replies (1) of 86

All Anadys needs is to pick a strong CEO and the valuation will correct. Wow—that’s quite an oversimplification! ANDS also needs to prove that ANA975 and ANA380 are viable drugs. The issues with 975 are well known so I won’t repeat them. Regarding ANA380, there’s a disconnect between Xanthopoulos’s best in class assertion and the fact that NVS opted not to license it by letting its exclusive option expire. The valuation will correct to a major degree if and when there are data to justify a correction, Until then, everything is window dressing.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next